FcRn
51 programs · 51 companies
Programs
51
Companies
51
Active Trials
30
Targeting FcRn
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| Cevizanubrutinib | Johnson & Johnson | Preclinical | Wilms | |
| Gelinaritide | AbbVie | Preclinical | HNSCC | |
| Talalemzoparlimab | Gilead Sciences | Phase 1 | RAACC | |
| Sovafutibatinib | Moderna | Approved | CTCLGA | |
| ITC-879 | Intra-Cellular | Approved | Bladder Ca | |
| JAZ-8729 | Jazz Pharma | Phase 2/3 | MSAS | |
| GLP-5658 | Galapagos | Phase 2/3 | CSUBreast Ca | |
| GRF-8977 | Grifols | Phase 1 | Heart FailureACC | |
| CSL-4765 | CSL Limited | Phase 1/2 | LN | |
| 187-8157 | Shanghai Junshi | Phase 2/3 | Breast Ca | |
| Rimalucimab | Aroa Biosurgery | Phase 3 | CTCL | |
| STA-IIT-774 | Stanford Medicine | Phase 1 | Obesity | |
| HOV-IIT-732 | HOVON | Phase 3 | Prostate Ca | |
| XTA-4333 | XtalPi | Approved | CholangiocarcinomaBreast Ca | |
| AGE-4274 | Agenus | Phase 1 | Huntington'sMS | |
| CLL-5354 | Cellectis | Preclinical | ALLHeart Failure | |
| Olparelsin | Flare Ther | Preclinical | CRCMS | |
| Rilubrutinib | Processa Pharma | Phase 1 | CRC | |
| Polarapivir | SpringWorks | NDA/BLA | CMLGA | |
| Doxaderotide | DiaMedica Therapeutics | Phase 1/2 | CRC | |
| NBS-1842 | NeuBase Therapeutics | NDA/BLA | LN | |
| NGM-3123 | NGM Biopharm | Phase 3 | IgANOCD | |
| Adagrainavolisib | G1 Therapeutics (Licella) | Phase 2/3 | CRCADPKD | |
| CAN-3547 | Can-Fite BioPharma | NDA/BLA | NBProstate Ca | |
| Tixacilimab | Paratek Pharma | Phase 1/2 | ACCCRC | |
| Liraratamab | Myokardia (BMS) | Approved | ALSMDD | |
| DER-1141 | Dermira (Lilly) | Preclinical | MCL | |
| Polainavolisib | Corvus (Angel) | Phase 2/3 | MDDET | |
| Rimafotisoran | Gloria Biosciences | Phase 2/3 | HS | |
| Mirituximab | Octant Bio | Phase 2 | MDSMG | |
| Sovazasiran | Kojin Ther | Phase 3 | NSCLC | |
| Rimasacituzumab | Deciphera | Phase 2 | CMLMCL | |
| Cevimavacamten | Arrowhead Pharma | Phase 1/2 | CFSCD | |
| 488-6881 | Sawai Group | Phase 2/3 | MG | |
| Mirinesiran | Noile-Immune | Phase 2 | CeliacFTD | |
| 532-7053 | Zydus Life | Phase 1 | Ovarian Ca | |
| Olpazasiran | Trillium (Pfizer) | Phase 3 | ADHDCholangiocarcinoma | |
| Doxabrutinib | Itamar Medical (Zoll) | Phase 2/3 | ADHD | |
| Lisotuximab | Hyloris | Phase 2/3 | ALLPTSD | |
| Polazasiran | Erytech Pharma | Phase 3 | MG | |
| Lisofotisoran | Ajanta Pharma | NDA/BLA | MGALS | |
| SUV-9449 | Suven Pharma | Phase 3 | ALLNMOSD | |
| BIO-IIT-514 | Bio-Manguinhos | Phase 1/2 | SMA | |
| Polabrutinib | Mega Lifesciences | Preclinical | EpilepsyLGS | |
| APN-2677 | Aspen Pharmacare | NDA/BLA | MCCSCLC | |
| CHI-IIT-951 | Chinese PLA General Hosp | Phase 2 | Thymoma | |
| PRI-IIT-139 | Princess Margaret | Preclinical | MCC | |
| WES-IIT-352 | West China Hosp | Phase 3 | DMD | |
| MSN-5549 | MSN Laboratories | NDA/BLA | UCGIST | |
| Lisoderotide | Walvax Biotech | Phase 1/2 | CLLMG | |
| ADA-2164 | Adamed | Approved | Bladder CaCrohn's |